Biocryst Pharmaceuticals Inc (BCRX) · Aug 5, 2026 · Company update

Quarterly results announced, but the financial release itself is absent.

Quarterly results announced, but the financial release itself is absent.

There is no earnings read to make from the supplied material. The 8-K cover filing only says BioCryst issued a second-quarter 2026 results release on August 5 and incorporates it as Exhibit 99.1; it contains none of the release’s revenue, earnings, cash, guidance, ORLADEYO sales, or pipeline-update details. (Item 2.02; Exhibit index)

That prevents a defensible beat-or-miss conclusion. Published pre-report estimates appeared to center around roughly $183 million–$188 million of revenue and about $0.12–$0.15 EPS, but the supplied filing provides no actual figures to compare against them. Calling this positive, negative, or even in line would be invention rather than analysis.

The only new information visible here is procedural, not economic. This is a standard results-announcement 8-K that furnishes, rather than files, the missing press release under Items 2.02 and 7.01. The substantive exhibit is required to determine what changed versus market expectations. (Items 2.02, 7.01; Exhibit 99.1)

Original filing on SEC EDGAR

More Biocryst Pharmaceuticals Inc news

Quarterly results announced, but the financial release itself is absent. | BCRX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.